A study of the epidemiology of severe sepsis in the United States determined the national prevalence to be 751,000 cases for the calendar year 1995 with a crude mortality of 28.6% or 215,000 cases (1) . The annual increase in severe sepsis cases was projected to be 1.5%, with the burgeoning elderly population accounting for both the highest incidence and mortality rates. Despite improvements in antimicrobial therapy and supportive care, these data indicate that improved approaches for the management of severe sepsis are a major unmet medical need (2) .
The lungs constitute the site of origin in at least 50% of the patients with severe sepsis (1, 3) . With 6 million cases, 500,000 hospitalizations, and 50,000 deaths from community-acquired pneumonia occurring annually (4) , new strategies are needed beyond the appropriate use of antibiotics and proper respiratory and supportive care to improve outcomes in patients with severe cases of pneumonia. Preclinical studies demonstrated that filgrastim (r-metHuG-CSF) can enhance both neutrophil production and function, and improve survival in a variety of animal models of pneumonia (5) . In a large (756 patients) placebo-controlled trial, filgrastim given as an adjunct to antibiotics in the treatment of severe community-acquired pneumonia promptly increased circulating neutrophil counts and was well tolerated (6) . Furthermore, in a large subgroup of the patients who had multilobar disease, filgrastim treatment accelerated radiologic resolution, reduced complications, and shortened hospitalization in the intensive care unit (6) . In various experimental models of sepsis, filgrastim-treated animals have lower mortality rates associated with greater clearance of bacteria and endotoxin and a reduction in cytokine levels compared with placebo controls. Results of a small phase 1/2 pneumonia sepsis study in a severely ill population (Acute Physiology and Chronic Health Evaluation II scores Ͼ25) demonstrated the ability of filgrastim to increase absolute neutrophil counts; filgrastim-treated patients had improved resolution of shock and a lower occurrence of mortality (7) . Filgrastim was well tolerated and, specifically, acute respiratory distress syndrome rates were not different between placebo and filgrastim-treated groups. Based on these encouraging preclinical and clinical data, it was hypothesized that the addition of filgrastim to a regimen of intravenous antibiotics would reduce the rate of mortality in patients with pneumonia and sepsis.
MATERIALS AND METHODS
Study Design. The institutional review boards of all participating institutions approved the study design, and all patients or legal guardians gave written informed consent before any study-specific tests were done.
The study design was multicenter, doubleblind, randomized, and placebo-controlled. Patients who met the eligibility requirements were randomized to receive filgrastim or placebo in a 1:1 ratio using a predetermined randomization list. A separate randomization list was generated for each center. Study drug was initiated as soon as possible (always within 24 hrs of meeting study entry criteria) and was continued for 5 days or until the white blood cell count was Ͼ75.0 ϫ 10 9 cells/L. Studyrelated observations, consisting of vital signs, onset of organ dysfunction, laboratory values, and adverse events, continued through day 10. Patient survival on day 29 was determined.
Patients. Adult patients (Ͼ18 yrs old) hospitalized with either community-acquired or nosocomial bacterial pneumonia were eligible for study entry if they met specific inclusion criteria. These criteria included presence of infiltrates on chest radiograph compatible with a diagnosis of bacterial pneumonia, confirmed by a positive culture of the blood, protected specimen brush, or bronchoalveolar lavage (for patients on ventilatory support Ն3 days). Patients had to have fever (temperature Ն38°C), tachypnea (Ͼ20 breaths/minute or need for mechanical ventilatory support), and tachycardia (heart rate Ͼ90 beats/minute). In addition, patients had to have a diagnosis of pneumonia-induced severe sepsis by at least one of the following organ dysfunctions: sepsis-induced hypotension, acute respiratory distress syndrome, disseminated intravascular coagulation, acute oliguria, or lactic acidosis as defined in the protocol.
Patients were not eligible for participation if they were pregnant or breastfeeding; had a life expectancy (unrelated to the acute infection) of Ͻ72 hrs, cardiogenic shock as the primary acute condition, uncontrolled hemorrhage, or the presence of full-thickness thermal or chemical burns (Ͼ20% of body surface); had a white blood cell count Ͼ40 ϫ 10 9 cells/L, had history of New York Heart Association class IV heart failure; had do-notresuscitate orders, or had known hypersensitivity to Escherichia coli-derived products.
Treatment. Filgrastim (300 g/day) or placebo (vehicle in an identical vial) (Amgen, Thousand Oaks, CA) were administered as a 30-min intravenous infusion for 5 days, until the white blood cell count was Ͼ75 ϫ 10 9 /L, or until the day intravenous antibiotics were discontinued, whichever came first. The study drug was administered as soon as possible and within 24 hrs of meeting criteria for severe sepsis and within 4 hrs of randomization. Subsequent doses were given at 24-hr intervals after the first dose and within 5 hrs after the results of a white blood cell count were known.
Supportive Care and Monitoring. Full supportive care was given as required. Concomitant medications, including antibiotics, were administered as medically indicated by the treating clinicians. Baseline assessments included clinical evaluation (vital signs, Acute Physiology and Chronic Health Evaluation II score, electrocardiogram, chest radiograph, arterial blood gases, and sputum and blood cultures). During the course of the study, vital signs and complete blood counts were recorded daily, and patients were monitored for organ dysfunction, adverse events, concomitant medications, blood transfusions, and procedures. Chest radiographs, arterial blood gases, and other blood panels were done as clinically indicted.
Study End Points and Sample Size. The primary efficacy end point was the occurrence of mortality through day 29. Secondary efficacy end points included occurrence of subsequent end-organ dysfunction through day 10, days on mechanical ventilatory support through day 29, time to death, and time to an intensive care unit discharge. The safety end points were the occurrence of adverse events through day 10, changes from baseline in laboratory parameters, and mortality through day 29.
A sample size of 700 patients was calculated to provide 80% power to detect a reduction in 28-day mortality from 35% in the placebo group to 25% in the filgrastim-treated group. The estimated placebo rate was based on the observed mortality rates in the sample populations with severe sepsis enrolled in previous Amgen-sponsored studies as well as the published literature.
Statistical Methods. The proportions of deaths occurring on or before day 29 and the proportion of patients with new end-organ dysfunction on or before day 10 were compared using the Cochran-Mantel-Haenszel test with stratification by center. A center-pooling algorithm was devised in which centers were pooled to ensure that each pooled center had at least one patient on each treatment and at least one experiencing each outcome.
Kaplan-Meier estimates of the distributions of survival time and time to intensive care unit discharge were compared between treatment groups with the log-rank test, and days on mechanical ventilatory support were compared with the Wilcoxon's rank-sum test.
Adverse events were tabulated by body system, severity, and relationship to study drug. No interim analysis was planned, and none was performed.
RESULTS

Patients
From April 1996 through December 1998, 701 patients from 96 hospital centers in the United States, Canada, Australia, and Europe were enrolled in this study and randomized to receive filgrastim (n ϭ 348) or placebo (n ϭ 353). Forty-four patients (6.3% of all patients) did not complete the study for reasons other than death.
The two study groups were balanced in terms of age, sex, race, and baseline comorbid medical disorders, including vital signs and blood gases ( Table 1 ). All patients who participated in this study presented with either community-acquired pneumonia (80%) or nosocomial pneumonia (20%); the distribution was approximately equal in both groups.
A blood culture was performed at baseline for 672 patients (96%) ( Table 2) , and a respiratory secretion culture was performed at baseline for 625 patients (89%) ( Table 3) . Twenty-nine percent of the patients were bacteremic, with Streptococcus pneumoniae and Staphylococcus aureus the most frequently found pathogens.
Drug Administration and Responses
A total of 699 patients received at least one dose of study drug and were evaluable for safety. Two patients died before receiving study drug (one in each group). Eighty-four percent of all patients received the complete 5-day course of study drug. The median highest white blood cell count (i.e., the median of the highest individual patient values) was 19.3 ϫ 10 9 cells/L in the placebo group and 31.7 ϫ 10 9 cells/L in the filgrastim group (Fig.  1) . The median time to each peak white blood cell count was 9 days in the placebo group and 4 days in the filgrastim group. Once filgrastim therapy was discontinued, the white blood cell count returned to baseline, usually within 3 days.
The most frequently prescribed antibiotics were third-generation cephalosporins (64% to 66%), followed by macrolides (53% to 56%), and aminoglycosides (40% to 44%). This usage is consistent with the broad-spectrum coverage administered to patients with severe pneumonia.
Study End Points
Efficacy End Points. A total of 191 patients died during the study, 90 in the placebo group and 101 in the filgrastim group. The occurrence of mortality through day 29 was 25.5% in the placebo group and 29.0% in the filgrastim group. This difference between the two groups was not statistically significant (p ϭ .383, Cochran-Mantel-Haenszel test stratified by pooled center). In patients with community-acquired pneumonia, the mortality rates were 24% (placebo) and 28% (filgrastim) compared with patients with nosocomial pneumonia with 31% (placebo) and 33% (filgrastim), respectively. These rates were not significantly different for the filgrastim and placebo groups in either form of severe pneumonia.
The median time to death was Ͼ28 days for both the placebo and filgrastim groups (Fig. 2) . The distributions were not significantly different between the treatment groups (p ϭ .261, log-rank test). Each covariate effect was significant: age (p ϭ .0001), number of endorgan dysfunctions (p ϭ .0001), bacteremia (p ϭ .0157), and Acute Physiology and Chronic Health Evaluation II Score (p ϭ .0004).
The overall occurrence of new endorgan dysfunctions was 40.0% in the placebo group and 42.6% in the filgrastim group (p ϭ .524 according to CochranMantel-Haenszel test stratified by pooled center). Among antibiotics administered during the study, only the use of quinolones in the filgrastim-treated group showed a strong trend toward reduced 28-day mortality. With any use of quinolones from day 1 to day 5, there was 40% mortality in quinolone-placebo group (31/78) compared with 29% mortality in the quinolone-filgrastim group (18/62; p ϭ .187; 95% confidence interval, 0.45-1.18). This represented an absolute decrease in mortality of 11% and a relative risk of .73 (a 27% rate reduction). No other trends were noted for other antibiotics between the placebo and filgrastimtreated groups.
A total of 686 patients (98%) were in an intensive care unit at study entry (placebo: n ϭ 345, 97.7%; filgrastim: n ϭ 341, 97.9%). The median time to intensive care unit discharge was 12 days in both groups (Fig. 3) . The distributions Given as number (percent). a ARDS is defined as (in the absence of overt cardiac disease): PAO 2 /FIO 2 ratio Յ200; diffuse bilateral infiltrates on chest radiograph; requirement for mechanical ventilation with positive end-expiratory pressure Ն5; pulmonary artery occlusion pressure Ͻ19 mm Hg if a pulmonary artery catheter was in place. The diagnosis of protocol-defined ARDS was made on the day all four criteria were met. Given as number (percent).
were not statistically significantly different between the treatment groups (p ϭ .780, log-rank test). No statistically significant difference was noted in days on mechanical ventilatory support (9.3 days in the placebo group and 9.6 days in the filgrastim-treated group; p ϭ .835, logrank test). Safety End Points. A total of 2,517 adverse events were reported among 336 (95%) evaluable patients receiving placebo, and 2,484 adverse events were reported among 338 (97%) evaluable patients receiving filgrastim. Adverse events were generally similar in type and frequency between the two treatment groups. Severe adverse events were comparable between the two treatment groups: 128 (36%) patients in the placebo group and 137 (39%) patients in the filgrastim group had severe or life-threatening adverse events. The most frequent severe or life-threatening adverse events reported with at least a 2% difference in frequency between the two treatment groups were renal insufficiency, acute respiratory distress syndrome, hypotension, cardiac arrest, and acidosis.
No clinically significant effect of filgrastim on laboratory values (other than white blood cell count) was observed. Filgrastim appeared to be safe and well tolerated when administered to 347 patients with pneumonia and severe sepsis.
DISCUSSION
Nosocomial pneumonia is frequently a fatal complication in hospitalized patients, particularly those who require mechanical ventilatory support for their medical problems (8, 9) , and communityacquired pneumonia is a major health problem in Western Europe and North America. In the United States, pneumonia is the leading cause of death from an infectious disease and the sixth highest cause of mortality from any cause (10) . Mortality rates are particularly high in elderly patients with community-acquired pneumonia of any etiology, even if not complicated by bacteremia (11) . Younger patients with pneumococcal pneumonia and sepsis also suffer high mortalities, usually in excess of 20% (12) . Improved therapeutic strategies are needed for patients who are severely ill with pneumonia and sepsis. A study that is focused on bacterial pneumonia with strict case definitions and entry criteria has the virtue of less heterogeneity of the study patients and fewer microbial etiologies to be covered by antimicrobial treatment. This contrasts with the many published studies of severe sepsis in which at least 10% of the patients had no identifiable source or etiology for sepsis and may not have had infection as the cause of the systemic inflammatory response (13) .
This study was conducted to determine whether filgrastim, when added to a course of intravenous antibiotics and other standard management strategies, would reduce the rate of mortality in hospitalized patients with severe pneumonia and sepsis. Filgrastim administration increased white blood cell counts to a median peak of 31.7 ϫ 10 9 cells/L from a baseline of 12.3 ϫ 10 9 cells/L, and were significantly higher than in the placebo group. Although the study drug was administered in a blinded fashion, this increase in white blood cell count could be considered to limit the blinding of the study. Because the outcome was not different between the two groups, this study-design limitation is negligible. The median age, nature and prevalence of comorbid conditions, severity of illness, rates of bacteremia, prevalence of organ failures, and the need for supportive mechanical ventilatory support at study entry were well balanced and similar to data from other published large studies (8, 14) . Mortality, the primary efficacy end point, was not significantly different between the placebo and filgrastim groups, regardless of whether the cause was community-acquired pneumonia or nosocomial pneumonia. In addition, no significant between-group differences were found for the secondary efficacy end points, including the occurrence of endorgan dysfunction, days on mechanical ventilatory support, time to death, and time to intensive care unit discharge. Severe adverse events were comparable between the two study groups. Acute respiratory distress syndrome was not unexpected in this patient population, and its frequency was within historical norms in both groups. Acute respiratory distress syndrome was reported in 41 (12%) patients in the placebo group and 56 (16%) patients in the filgrastimtreated group.
A number of reasons are possible for this failure to detect any clinical benefit from adjunctive filgrastim treatment of a severe infection in which phagocytes are paramount in host defense. These might include faulty validity of the underlying hypothesis, inadequate dosage or biological activity of exogenously administered G-CSF, improper study design, or failed execution.
It is known that the amount of circulating endogenous G-CSF increases rapidly in patients with bacterial infections, and most evidence supports a primary role for this growth factor in generating the neutrophilic leukocytosis in such patients (15) . Particularly high levels of endogenous G-CSF have been reported in patients with sepsis and septic shock; these paralleled similar elevations in interleukin-6 and leukemia inhibitor factor (16) . The prompt and significant elevation of absolute neutrophil count in the filgrastim recipients in this present study indicates that the dosage chosen had appreciable biological activity, although a lack of augmentation of other known phagocytic activities in the setting of severe sepsis cannot be excluded (17) .
The choice of the antibiotic therapy that is paired with filgrastim administration may be important for optimizing favorable anti-infective interactions in these severely ill patients with sepsis arising from the lungs. As a class, quinolones exhibit excellent tissue and cell penetration compared with ␤-lactams (18) . In addition, filgrastim has been reported to increase the intracellular uptake by neutrophils of some antibiotics, including ciprofloxacin (19) . Our results indicate that patients receiving filgrastim and antibiotic therapy that included a quinolone for their initial treatment showed a strong trend toward decreased mortality. It is conceivable that if quinolones had been used more broadly, the increased numbers of patients treated may have been sufficient for a statistically significant result.
Regarding the study design, the timing of the administration of filgrastim may have been too late in the course to alter the clinical outcome of these severely ill patients. In nearly all the preclinical studies of challenge models with bacteria or bacterial endotoxin, filgrastim was most beneficial when given either simultaneously with or before the infectious agent or endotoxin. Much less benefit was observed when filgrastim administration was delayed until well after initiation of the experimental infection (5). In the published clinical studies of filgrastim as an adjunct in the management of bacterial infections, beneficial results were most consistently observed when filgrastim was given as prophylaxis to patients at high risk to develop postoperative pneumonia or soft-tissue infections (20, 21) or when administered early in the management of nonseptic diabetic patients with localized soft-tissue infection (22) . In a prospective, placebocontrolled trial of filgrastim in patients with bacterial pneumonia, only patients with multilobar disease without severe sepsis or multiple organ failures exhibited a strong trend toward reduced mortality (6) .
After this study was designed, additional knowledge emerged about the nature of the dynamic balance between systemic inflammatory and counterinflammatory mediators that evolves during the course of severe sepsis. Although the initial systemic responses to severe infection are accompanied by sharp increases in circulating inflammatory mediators, later in the course, the balance characteristically shifts toward the anti-inflammatory and immunosuppressive spectrum (23) (24) (25) . In fact, the degree of increase in plasma concentrations of a variety of endogenous antiinflammatory mediators correlates strongly with adverse outcomes (26, 27) . Furthermore, the extent of systemic immunosuppression, as measured by the reduced expression of human leukocyte antigen-DR on circulating mononuclear cells, also correlates directly with poor outcomes (28) . Several cytokines and growth factors, including G-CSF, appear to have a key role in the host's attempts to restore systemic homeostasis in severe sepsis. In so doing, their systemic functions may be quite different from their actions at local sites of infection (29 -31) . The initial responses at the local infection site are predominantly inflammatory and devoted to eliminating the offending pathogens. In contrast, the early systemic responses are usually anti-inflammatory and focus on restricting some of the damaging systemic consequences of severe local infection (32) . With respect to G-CSF, its enhanced production in response to an infectious challenge is critical for recruiting and optimizing phagocytic activity at local sites, which are involved in the removal of offending pathogens (15, 17, 32) . Conversely, the major systemic effects of G-CSF are both anti-inflammatory and immunosuppressive and appear to be focused on inhibition of the production and actions of inflammatory cytokines, as well as in expanding a T-helper lymphocyte response that might eventually lead to the production of specific antibodies to neutralize microbial pathogenic factors (31, (33) (34) (35) .
CONCLUSIONS
Delaying the administration of filgrastim to patients with severe infection until a time that is well after initiation of antimicrobial treatment and the development of organ failures and systemic immunosuppression may provide little additional anti-infective benefit and is unlikely to restore systemic immunity. Further studies using these principles to explore the timing and ability of filgrastim to ameliorate or prevent the consequences of severe bacterial infection will be of great interest.
